Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Mark Stephen Huberman, M.D.


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Neal JW, Costa DB, Muzikansky A, Shrager JB, Lanuti M, Huang J, Ramachandran KJ, Rangachari D, Huberman MS, Piotrowska Z, Kris MG, Azzoli CG, Sequist LV, Chaft JE. Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2021 01; 5:325-332. PMID: 34151132; PMCID: PMC8205223.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  2. Sehgal K, Bulumulle A, Brody H, Gill RR, Macherla S, Qilleri A, McDonald DC, Cherry CR, Shea M, Huberman MS, VanderLaan PA, Weiss GJ, Walker PR, Costa DB, Rangachari D. Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non-small-cell Lung Cancer. Clin Lung Cancer. 2021 05; 22(3):e379-e389. PMID: 32653295.
    Citations: 5     Fields:    Translation:Humans
  3. Jorge SE, Lucena-Araujo AR, Yasuda H, Piotrowska Z, Oxnard GR, Rangachari D, Huberman MS, Sequist LV, Kobayashi SS, Costa DB. Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. Clin Cancer Res. 2020 May 01; 26(9):2277. PMID: 32358026.
    Citations:    Fields:    
  4. Jorge SE, Lucena-Araujo AR, Yasuda H, Piotrowska Z, Oxnard GR, Rangachari D, Huberman MS, Sequist LV, Kobayashi SS, Costa DB. EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas. Clin Cancer Res. 2018 12 15; 24(24):6548-6555. PMID: 30154228; PMCID: PMC6295229.
    Citations: 24     Fields:    Translation:HumansAnimalsCells
  5. Ostios-Garcia L, Faig J, Leonardi GC, Adeni AE, Subegdjo SJ, Lydon CA, Rangachari D, Huberman MS, Sehgal K, Shea M, VanderLaan PA, Cheng MP, Marty FM, Hammond SP, Costa DB, Awad MM. Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer. J Thorac Oncol. 2018 07; 13(7):1037-1042. PMID: 29631035.
    Citations: 34     Fields:    Translation:HumansCells
  6. VanderLaan PA, Rangachari D, Majid A, Parikh MS, Gangadharan SP, Kent MS, McDonald DC, Huberman MS, Kobayashi SS, Costa DB. Tumor biomarker testing in non-small-cell lung cancer: A decade of change. Lung Cancer. 2018 02; 116:90-95. PMID: 29413057.
    Citations: 16     Fields:    Translation:Humans
  7. Rangachari D, Le X, Shea M, Huberman MS, VanderLaan PA, Kobayashi SS, Costa DB. Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy. J Thorac Oncol. 2017 11; 12(11):e175-e177. PMID: 28611010.
    Citations: 7     Fields:    Translation:Humans
  8. Shields H, Li J, Pelletier S, Wang H, Freedman R, Mamon H, Ng A, Freedman A, Come S, Avigan D, Huberman M, Recht A. Persistence of dysphagia and odynophagia after mediastinal radiation and chemotherapy in patients with lung cancer or lymphoma. Dis Esophagus. 2017 02 01; 30(2):1-8. PMID: 27247116.
    Citations: 1     Fields:    Translation:HumansPHPublic Health
  9. VanderLaan PA, Rangachari D, Mockus SM, Spotlow V, Reddi HV, Malcolm J, Huberman MS, Joseph LJ, Kobayashi SS, Costa DB. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. Lung Cancer. 2017 04; 106:17-21. PMID: 28285689.
    Citations: 80     Fields:    Translation:Humans
  10. Rangachari D, VanderLaan PA, Shea M, Le X, Huberman MS, Kobayashi SS, Costa DB. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 =50% Expression in Lung Adenocarcinoma. J Thorac Oncol. 2017 05; 12(5):878-883. PMID: 28104537.
    Citations: 57     Fields:    Translation:Humans
  11. Rangachari D, Drake L, Huberman MS, McDonald DC, VanderLaan PA, Folch E, Costa DB. Rapidly fatal advanced EGFR-mutated lung cancers and the need for rapid tumor genotyping in clinical practice. Cancer Treat Commun. 2016; 9:41-43. PMID: 28111612; PMCID: PMC5241076.
    Citations: 2     
  12. Lucena-Araujo AR, Moran JP, VanderLaan PA, Dias-Santagata D, Folch E, Majid A, Kent MS, Gangadharan SP, Rangachari D, Huberman MS, Kobayashi SS, Costa DB. De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers. Lung Cancer. 2016 09; 99:17-22. PMID: 27565908.
    Citations: 8     Fields:    Translation:HumansCells
  13. Sheikine Y, Rangachari D, McDonald DC, Huberman MS, Folch ES, VanderLaan PA, Costa DB. EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review. Clin Lung Cancer. 2016 11; 17(6):483-492. PMID: 27381270.
    Citations: 13     Fields:    Translation:Humans
  14. Costa DB, Jorge SE, Moran JP, Freed JA, Zerillo JA, Huberman MS, Kobayashi SS. Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas. J Thorac Oncol. 2016 06; 11(6):918-23. PMID: 26964772.
    Citations: 18     Fields:    Translation:HumansCells
  15. Shea M, Huberman MS, Costa DB. Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma. J Thorac Oncol. 2016 07; 11(7):e81-2. PMID: 26845194.
    Citations: 6     Fields:    Translation:Humans
  16. Jorge SE, Schulman S, Freed JA, VanderLaan PA, Rangachari D, Kobayashi SS, Huberman MS, Costa DB. Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. Lung Cancer. 2015 Dec; 90(3):369-74. PMID: 26791794.
    Citations: 33     Fields:    Translation:HumansCells
  17. Le X, Freed JA, VanderLaan PA, Huberman MS, Rangachari D, Jorge SE, Lucena-Araujo AR, Kobayashi SS, Balasubramanian S, He J, Chudnovsky Y, Miller VA, Ali SM, Costa DB. Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling. Clin Lung Cancer. 2015 Sep; 16(5):e105-9. PMID: 25922291.
    Citations: 5     Fields:    Translation:Humans
  18. Le X, Desai NV, Majid A, Karp RS, Huberman MS, Rangachari D, Kent MS, Gangadharan SP, Folch E, VanderLaan PA, Costa DB. De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors. Lung Cancer. 2015 Apr; 88(1):70-3. PMID: 25700797.
    Citations: 12     Fields:    Translation:Humans
  19. Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, Uhlmann EJ, Wong ET, Dahlberg SE, Huberman MS, Costa DB. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer. 2015 Apr; 88(1):108-11. PMID: 25682925.
    Citations: 145     Fields:    Translation:Humans
  20. Rangachari D, VanderLaan PA, Le X, Folch E, Kent MS, Gangadharan SP, Majid A, Haspel RL, Joseph LJ, Huberman MS, Costa DB. Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice. Cancer Treat Commun. 2015; 4:174-181. PMID: 26601054; PMCID: PMC4653729.
    Citations: 16     
  21. Vanderlaan PA, Yamaguchi N, Folch E, Boucher DH, Kent MS, Gangadharan SP, Majid A, Goldstein MA, Huberman MS, Kocher ON, Costa DB. Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer. Lung Cancer. 2014 Apr; 84(1):39-44. PMID: 24513263.
    Citations: 61     Fields:    Translation:Humans
  22. Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S, Ishioka K, Yamaguchi N, Hanna M, Oxnard GR, Lathan CS, Moran T, Sequist LV, Chaft JE, Riely GJ, Arcila ME, Soo RA, Meyerson M, Eck MJ, Kobayashi SS, Costa DB. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 2013 Dec 18; 5(216):216ra177. PMID: 24353160; PMCID: PMC3954775.
    Citations: 174     Fields:    Translation:HumansCells
  23. Folch E, Yamaguchi N, VanderLaan PA, Kocher ON, Boucher DH, Goldstein MA, Huberman MS, Kent MS, Gangadharan SP, Costa DB, Majid A. Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer. J Thorac Oncol. 2013 Nov; 8(11):1438-1444. PMID: 24128714.
    Citations: 19     Fields:    Translation:Humans
  24. Yamaguchi N, Vanderlaan PA, Folch E, Boucher DH, Canepa HM, Kent MS, Gangadharan SP, Majid A, Kocher ON, Goldstein MA, Huberman MS, Costa DB. Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. Lung Cancer. 2013 Oct; 82(1):31-7. PMID: 23932486; PMCID: PMC3800098.
    Citations: 29     Fields:    Translation:Humans
  25. Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, Bonomi P, Brahmer J, Chen LC, Sandler A, Belani CP, Webb T, Harper H, Huberman M, Ramalingam S, Wong KK, Teofilovici F, Guo W, Shapiro GI. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res. 2013 Jun 01; 19(11):3068-77. PMID: 23553849.
    Citations: 110     Fields:    Translation:HumansCTClinical Trials
  26. Kobayashi S, Canepa HM, Bailey AS, Nakayama S, Yamaguchi N, Goldstein MA, Huberman MS, Costa DB. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2013 Jan; 8(1):45-51. PMID: 23242437.
    Citations: 64     Fields:    Translation:HumansCells
  27. Nguyen KS, Sanford RA, Huberman MS, Goldstein MA, McDonald DM, Farquhar M, Gangadharan SP, Kent MS, Michaud G, Majid A, Berman SM, Aronovitz JA, Nedea EA, Boiselle PM, Cohen DW, Kobayashi S, Costa DB. Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer center. J Oncol Pract. 2012 Jan; 8(1):57-62. PMID: 22548013.
    Citations: 2     Fields:    
  28. Britt GJ, Gaughan EM, Nguyen KS, Warner JL, Goldstein MA, Huberman MS, Costa DB. Case series of treatment approaches in fit nonagenarians with stage IV non-small-cell lung cancer. J Thorac Dis. 2011 Jun; 3(2):141-3. PMID: 22263078.
  29. Nguyen KH, Huberman M, Goldstein M, Kobayashi S, Costa DB. Patterns of care for non-small cell lung cancer at an academic institution affiliated with a National Cancer Institute-designated cancer center: Beth Israel Deaconess Medical Center. J Clin Oncol. 2011 May 20; 29(15_suppl):e18034. PMID: 28020790.
  30. Neal JW, Heist RS, Fidias P, Temel JS, Huberman M, Marcoux JP, Muzikansky A, Lynch TJ, Sequist LV. Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Thorac Oncol. 2010 Nov; 5(11):1855-8. PMID: 20975380.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  31. Yeo WL, Riely GJ, Yeap BY, Lau MW, Warner JL, Bodio K, Huberman MS, Kris MG, Tenen DG, Pao W, Kobayashi S, Costa DB. Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations. J Thorac Oncol. 2010 Jul; 5(7):1048-53. PMID: 20512075.
    Citations: 37     Fields:    Translation:HumansCells
  32. Sequist LV, Fidias PM, Temel JS, Kolevska T, Rabin MS, Boccia RV, Burris HA, Belt RJ, Huberman MS, Melnyk O, Mills GM, Englund CW, Caldwell DC, Keck JG, Meng L, Jones M, Brown GL, Edelman MJ, Lynch TJ. Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer. J Thorac Oncol. 2009 Nov; 4(11):1389-96. PMID: 19701107.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  33. Ye C, Masterman JR, Huberman MS, Gangadharan SP, McDonald DC, Kent MS, DeCamp MM. Subdivision of the T1 size descriptor for stage I non-small cell lung cancer has prognostic value: a single institution experience. Chest. 2009 Sep; 136(3):710-715. PMID: 19525360.
    Citations: 2     Fields:    Translation:Humans
  34. Jackman DM, Cioffredi L, Lindeman NI, Morse LK, Lucca J, Weckstein D, Huberman MS, Lynch TJ, Johnson BE, Janne PA. Phase II trial of erlotinib in chemotherapy-naive women with advanced pulmonary adenocarcinoma. J Clin Oncol. 2009 May 20; 27(15_suppl):8065. PMID: 27962638.
  35. Wong ET, Huberman M, Lu XQ, Mahadevan A. Bevacizumab reverses cerebral radiation necrosis. J Clin Oncol. 2008 Dec 01; 26(34):5649-50. PMID: 18981459.
    Citations: 38     Fields:    Translation:HumansPHPublic Health
  36. Costa DB, Nguyen KS, Cho BC, Sequist LV, Jackman DM, Riely GJ, Yeap BY, Halmos B, Kim JH, Jänne PA, Huberman MS, Pao W, Tenen DG, Kobayashi S. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res. 2008 Nov 01; 14(21):7060-7. PMID: 18981003; PMCID: PMC2596582.
    Citations: 70     Fields:    Translation:Humans
  37. Heist RS, Fidias P, Huberman M, Ardman B, Sequist LV, Temel JS, Lynch TJ. A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer. J Thorac Oncol. 2008 Oct; 3(10):1153-8. PMID: 18827612.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  38. Costa DB, Cho BC, Sequist LV, Riely GJ, Halmos B, Kim J, Huberman MS, Pao W, Tenen DG, Kobayashi S. Lack of efficacy of erlotinib in most EGFR mutated non-small cell lung cancers (NSCLCs) with acquired resistance to gefitinib. J Clin Oncol. 2008 May 20; 26(15_suppl):8105. PMID: 27948816.
  39. Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG, Kobayashi S. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 2007 Oct; 4(10):1669-79; discussion 1680. PMID: 17973572.
    Citations: 238     Fields:    Translation:HumansCells
  40. Costa DB, Kobayashi S, Tenen DG, Huberman MS. Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer. 2007 Oct; 58(1):95-103. PMID: 17610986.
    Citations: 64     Fields:    Translation:Humans
  41. Dragovich T, Huberman M, Von Hoff DD, Rowinsky EK, Nadler P, Wood D, Hamilton M, Hage G, Wolf J, Patnaik A. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Chemother Pharmacol. 2007 Jul; 60(2):295-303. PMID: 17149608.
    Citations: 15     Fields:    Translation:HumansCTClinical Trials
  42. Lam P, Berman S, Thurer R, Ashiku S, DeCamp M, Goldstein M, Schumer S, Halmos B, Karp D, Coute D, Bergman M, Boyd-Sirard C, Ou SH, Muzikansky A, Woodard C, Huberman M. Phase II trial of sequential chemotherapy followed by chemoradiation, surgery, and postoperative chemotherapy for the treatment of stage IIIA/IIIB non-small-cell lung cancer. Clin Lung Cancer. 2006 Sep; 8(2):122-9. PMID: 17026813.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  43. Costa DB, Huberman MS. Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib. Diabetes Care. 2006 Jul; 29(7):1711. PMID: 16801611.
    Citations: 16     Fields:    Translation:Humans
  44. Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jänne PA. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006 Jul 01; 12(13):3908-14. PMID: 16818686.
    Citations: 224     Fields:    Translation:Humans
  45. Sequist LV, Fidias P, Temel J, Kennedy BA, Ostler PA, Rabin MS, Huberman M, Keck J, Brown GL, Lynch TJ. Phase I-II trial of TLK286, a novel glutathione analog prodrug, in combination with carboplatin (C) and paclitaxel (P) as first-line treatment for advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2005 Jun; 23(16_suppl):7275. PMID: 27945488.
  46. Mayer S, Cypess AM, Kocher ON, Berman SM, Huberman MS, Hartzband PI, Halmos B. Uncommon presentations of some common malignancies: Case 1. Sequential paraneoplastic endocrine syndromes in small-cell lung cancer. J Clin Oncol. 2005 Feb 20; 23(6):1312-4. PMID: 15718329.
    Citations: 11     Fields:    Translation:Humans
  47. Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabárbara P, Bonomi P. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol. 2004 Aug 15; 22(16):3238-47. PMID: 15310767.
    Citations: 237     Fields:    Translation:HumansCTClinical Trials
  48. Porterfield BW, Dragovich T, Patnaik A, Rowinsky E, Huberman M, Clinebell T, Hamilton M, Zitelli A, Nadler P, Wood D. Erlotinib + gemcitabine in patients with unresectable pancreatic carcinoma: Results from a phase IB trial. J Clin Oncol. 2004 Jul 15; 22(14_suppl):4110. PMID: 28014524.
  49. Petrovich Z, Lieskovsky G, Stein JP, Huberman M, Skinner DG. Comparison of surgery alone with surgery and adjuvant radiotherapy for pT3N0 prostate cancer. BJU Int. 2002 Apr; 89(6):604-11. PMID: 11942974.
    Citations: 7     Fields:    Translation:Humans
  50. Petrovich Z, Lieskovsky G, Langholz B, Huberman M, Streeter O, Skinner DG. Nonrandomized comparison of surgery with and without adjuvant pelvic irradiation for patients with pT3N0 adenocarcinoma of the prostate. Am J Clin Oncol. 2001 Dec; 24(6):537-46. PMID: 11801750.
    Citations:    Fields:    Translation:Humans
  51. Rabey JM, Sagi I, Huberman M, Melamed E, Korczyn A, Giladi N, Inzelberg R, Djaldetti R, Klein C, Berecz G. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol. 2000 Nov-Dec; 23(6):324-30. PMID: 11575866.
    Citations: 33     Fields:    Translation:HumansCTClinical Trials
  52. Boiselle PM, Morrin MM, Huberman MS. Gemcitabine pulmonary toxicity: CT features. J Comput Assist Tomogr. 2000 Nov-Dec; 24(6):977-80. PMID: 11105721.
    Citations: 6     Fields:    Translation:Humans
  53. Vakil E, Kahan S, Huberman M, Osimani A. Motor and non-motor sequence learning in patients with basal ganglia lesions: the case of serial reaction time (SRT). Neuropsychologia. 2000; 38(1):1-10. PMID: 10617287.
    Citations: 30     Fields:    Translation:Humans
  54. Stram DO, Langholz B, Huberman M, Thomas DC. Correcting for exposure measurement error in a reanalysis of lung cancer mortality for the Colorado Plateau Uranium Miners cohort. Health Phys. 1999 Sep; 77(3):265-75. PMID: 10456497.
    Citations: 11     Fields:    Translation:HumansPHPublic Health
  55. Sanz-Altamira PM, Ferrante K, Jenkins RL, Lewis WD, Huberman MS, Stuart KE. A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma. Cancer. 1998 Jun 15; 82(12):2321-5. PMID: 9635523.
    Citations: 19     Fields:    Translation:HumansCTClinical Trials
  56. Sanz-Altamira PM, Spence LD, Huberman MS, Posner MR, Steele G, Perry LJ, Stuart KE. Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial. Dis Colon Rectum. 1997 Jul; 40(7):770-5. PMID: 9221850.
    Citations: 21     Fields:    Translation:HumansCTClinical Trials
  57. Eder JP, Rubin E, Stone R, Bryant M, Xu G, Supko J, Kinchla N, Lynch T, Hurwitz S, Rodriguez D, Shapiro C, Toppmeyer D, Grossbard M, Vosburg E, Huberman M, Schnipper L, Shulman L, Kufe DW. Trials of 9-amino-20(S)-camptothecin in Boston. Ann N Y Acad Sci. 1996 Dec 13; 803:247-55. PMID: 8993518.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  58. Stuart K, Tessitore J, Huberman M. 5-Fluorouracil and alpha-interferon in hepatocellular carcinoma. Am J Clin Oncol. 1996 Apr; 19(2):136-9. PMID: 8610636.
    Citations: 4     Fields:    Translation:Humans
  59. Anand A, Huberman M. Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer. 1995 Sep 01; 76(5):916-7. PMID: 8625200.
    Citations: 5     Fields:    Translation:Humans
  60. Stuart K, Posner M, Campbell K, Huberman M. Cisplatin and chronic oral etoposide as salvage therapy for advanced colorectal carcinoma. Am J Clin Oncol. 1995 Aug; 18(4):300-2. PMID: 7625370.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  61. Eyre RC, Huberman MS, Balogh K. Non-Hodgkin's lymphoma of the kidney with inferior vena caval extension. Urol Int. 1993; 51(1):43-5. PMID: 8333090.
    Citations:    Fields:    Translation:HumansCells
  62. Jessup JM, Posner M, Huberman M. Influence of multimodality therapy on the management of pancreas carcinoma. Semin Surg Oncol. 1993 Jan-Feb; 9(1):27-32. PMID: 8356381.
    Citations: 3     Fields:    Translation:Humans
  63. Jessup JM, Posner M, Huberman M, LoCicero J, Stone M, Steele G. Efficacy of multimodality therapy in gastric adenocarcinoma. Semin Surg Oncol. 1993 Jan-Feb; 9(1):19-26. PMID: 8356380.
    Citations: 2     Fields:    Translation:Humans
  64. Posner MR, Bleday R, Huberman M, Jessup JM, Busse P, Steele G. Impact of combined modality therapy on the treatment of adenocarcinoma of the colon. Semin Surg Oncol. 1993 Jan-Feb; 9(1):33-8. PMID: 8356383.
    Citations: 1     Fields:    Translation:Humans
  65. Huberman M, Bering H, Fallon B, Tessitore J, Sonnenborn H, Paul S, Zeffren J, Levitt D, Groopman J. A phase I study of an outpatient regimen of recombinant human interleukin-2 and alpha-2a-interferon in patients with solid tumors. Cancer. 1991 Oct 15; 68(8):1708-13. PMID: 1913512.
    Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
  66. Steele G, Busse P, Huberman MS, LeClair JM, Falchuk ZM, Mayer RJ, Bothe A, Ravikumar TS, Stone M, Jessup JM. A pilot study of sphincter-sparing management of adenocarcinoma of the rectum. Arch Surg. 1991 Jun; 126(6):696-701; discussion 701-2. PMID: 2039356.
    Citations: 7     Fields:    Translation:Humans
  67. Mittelman A, Huberman M, Puccio C, Fallon B, Tessitore J, Savona S, Eyre R, Gafney E, Wick M, Skelos A, et al. A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma. Cancer. 1990 Aug 15; 66(4):664-9. PMID: 2386896.
    Citations: 2     Fields:    Translation:Humans
  68. Cohen MC, Huberman MS, Nesto RW. Interferon alfa-induced cardiac dysfunction. N Engl J Med. 1990 May 17; 322(20):1469. PMID: 2330016.
    Citations:    Fields:    Translation:Humans
  69. Bern MM, Lokich JJ, Wallach SR, Bothe A, Benotti PN, Arkin CF, Greco FA, Huberman M, Moore C. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med. 1990 Mar 15; 112(6):423-8. PMID: 2178534.
    Citations: 91     Fields:    Translation:HumansCTClinical Trials
  70. Cohen MC, Huberman MS, Nesto RW. Recombinant alpha 2 interferon-related cardiomyopathy. Am J Med. 1988 Oct; 85(4):549-51. PMID: 3177405.
    Citations: 14     Fields:    Translation:Humans
  71. Bern MM, Wallach SR, Arkin CF, Lokich JJ, Huberman MS, Anderson NR, Corkery JC, Paul SD, Phillips DF, Sonneborn HA, et al. Etoposide in combination with cytarabine, doxorubicin, and 6-thioguanine for treatment of acute nonlymphoblastic leukemia in a protocol adjusted for age. Cancer Treat Rep. 1987 Feb; 71(2):201-3. PMID: 3802115.
    Citations: 2     Fields:    Translation:Humans
  72. Huberman M, Lokich J, Greene R, Paul S, Phillips D, Sonneborn H, Zipoli T. Vinblastine plus cisplatin in advanced non-small cell lung cancer: lack of advantage for vinblastine infusion schedule. Cancer Treat Rep. 1986 Feb; 70(2):287-9. PMID: 3004727.
    Citations: 1     Fields:    Translation:Humans
  73. Huberman MS, Lokich JJ, Hill T, Kaldany A, Kassis A, Price T, Moore C, Davis S, Kasulis P, Monaco AP, et al. Non-human primate (baboon) anti-carcinoembryonic antigen antibody infusion in patients with metastatic adenocarcinoma. A phase I study. Cancer Immunol Immunother. 1986; 23(2):137-42. PMID: 3490911.
    Citations:    Fields:    Translation:HumansAnimals
  74. Matelski H, Greene R, Huberman M, Lokich J, Zipoli T. Randomized trial of estrogen vs. tamoxifen therapy for advanced breast cancer. Am J Clin Oncol. 1985 Apr; 8(2):128-33. PMID: 3914839.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  75. Groopman JE, Sarngadharan MG, Salahuddin SZ, Buxbaum R, Huberman MS, Kinniburgh J, Sliski A, McLane MF, Essex M, Gallo RC. Apparent transmission of human T-cell leukemia virus type III to a heterosexual woman with the acquired immunodeficiency syndrome. Ann Intern Med. 1985 Jan; 102(1):63-6. PMID: 2981497.
    Citations:    Fields:    Translation:HumansCells
  76. Matelski HW, Lokich JJ, Huberman MS, Zipoli TE, Paul S, Sonneborn H, Philips D. Adriamycin, cyclophosphamide, and etoposide (VP-16-213) in extensive-stage small cell lung cancer. Am J Clin Oncol. 1984 Dec; 7(6):729-32. PMID: 6099053.
    Citations: 1     Fields:    Translation:Humans
  77. Huberman MS. Comparison of systemic chemotherapy with hepatic arterial infusion in metastatic colorectal carcinoma. Semin Oncol. 1983 Jun; 10(2):238-48. PMID: 6223374.
    Citations: 4     Fields:    Translation:Humans
  78. Levenson RM, Ihde DC, Huberman MS, Cohen MH, Bunn PA, Minna JD. Phase II trial of cisplatin in small cell carcinoma of the lung. Cancer Treat Rep. 1981 Sep-Oct; 65(9-10):905-7. PMID: 6268297.
    Citations: 4     Fields:    Translation:Humans
  79. Bunn PA, Huberman MS, Whang-Peng J, Schechter GP, Guccion JG, Matthews MJ, Gazdar AF, Dunnick NR, Fischmann AB, Ihde DC, Cohen MH, Fossieck B, Minna JD. Prospective staging evaluation of patients with cutaneous T-cell lymphomas. Demonstration of a high frequency of extracutaneous dissemination. Ann Intern Med. 1980 Aug; 93(2):223-30. PMID: 6967710.
    Citations: 7     Fields:    Translation:HumansCells
  80. Huberman MS, Bunn PA, Matthews MJ, Ihde DC, Gazdar AF, Cohen MH, Minna JD. Hepatic involvement in the cutaneous T-cell lymphomas: results of percutaneous biopsy and peritoneoscopy. Cancer. 1980 Apr 01; 45(7):1683-8. PMID: 6445224.
    Citations: 1     Fields:    Translation:HumansCells
  81. Huberman M, Fossieck BE, Bunn PA, Cohen MH, Ihde DC, Minna JD. Herpes zoster and small cell bronchogenic carcinoma. Am J Med. 1980 Feb; 68(2):214-8. PMID: 6243858.
    Citations:    Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Huberman's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (333)
Co-Authors (72)
Similar People (60)
Same Department 
Physical Neighbors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.